Everest Medicines Limited (FRA:6HN)

Market Cap	1.48B -15.4%
Revenue (ttm)	101.18M +103.4%
Net Income	-78.30M
EPS	-0.24
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	4.480
Previous Close	4.120
Day's Range	4.480 - 4.480
52-Week Range	4.000 - 8.250
Beta	n/a
RSI	41.52
Earnings Date	Mar 29, 2026

About Everest Medicines

Everest Medicines Limited, a biopharmaceutical company, engages in the discovery, license-in, development, and commercialization of therapies and vaccines to address critical unmet medical needs in Greater China and other Asia Pacific markets. Its pipeline includes Nefecon, an oral formulation of budesonide for the treatment of immunoglobulin nephropathy (IgAN); Xerava, a fully synthetic fluorocycline intravenous antibiotic for the treatment of infections caused by susceptible gram-positive, gram-negative, and anaerobic pathogens; Taniborbactam...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2017
• Employees: 722
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 6HN

Financial Performance

In 2024, Everest Medicines's revenue was 706.68 million, an increase of 461.16% compared to the previous year's 125.93 million. Losses were -1.04 billion, 23.3% more than in 2023.

Financial numbers in CNY